$EGRX
EAGLE PHARMACEUTICALS, INC.

2014 Q1 Form 10-Q Financial Statement

#000082787114000010 Filed on May 15, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1
Revenue $5.005M $2.481M
YoY Change 101.75%
Cost Of Revenue $3.360M $1.313M
YoY Change 155.88%
Gross Profit $1.645M $1.168M
YoY Change 40.88%
Gross Profit Margin 32.87% 47.07%
Selling, General & Admin $1.454M $2.949M
YoY Change -50.69%
% of Gross Profit 88.39% 252.53%
Research & Development $3.794M $2.525M
YoY Change 50.26%
% of Gross Profit 230.64% 216.24%
Depreciation & Amortization $29.00K
YoY Change
% of Gross Profit 1.76%
Operating Expenses $8.608M $6.787M
YoY Change 26.83%
Operating Profit -$3.603M -$4.306M
YoY Change -16.33%
Interest Expense $1.000K $144.9K
YoY Change -99.31%
% of Operating Profit
Other Income/Expense, Net -$376.0K -$497.8K
YoY Change -24.46%
Pretax Income -$3.979M -$4.804M
YoY Change -17.17%
Income Tax -$1.295M $0.00
% Of Pretax Income
Net Earnings -$2.684M -$4.804M
YoY Change -44.13%
Net Earnings / Revenue -53.63% -193.64%
Basic Earnings Per Share -$0.36
Diluted Earnings Per Share -$0.36
COMMON SHARES
Basic Shares Outstanding 8.862M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.90M
YoY Change
Cash & Equivalents $54.88M $3.653M
Short-Term Investments
Other Short-Term Assets $212.1K
YoY Change
Inventory
Prepaid Expenses
Receivables $7.820M
Other Receivables $0.00
Total Short-Term Assets $63.53M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $377.5K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $45.00K
YoY Change
Total Long-Term Assets $422.5K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $63.53M
Total Long-Term Assets $422.5K
Total Assets $63.96M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.458M
YoY Change
Accrued Expenses $7.116M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.27M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $19.27M
Total Long-Term Liabilities $0.00
Total Liabilities $19.30M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$92.14M
YoY Change
Common Stock $14.02K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.69M
YoY Change
Total Liabilities & Shareholders Equity $63.96M
YoY Change

Cashflow Statement

Concept 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$2.684M -$4.804M
YoY Change -44.13%
Depreciation, Depletion And Amortization $29.00K
YoY Change
Cash From Operating Activities -$2.071M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $28.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$28.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $47.01M
YoY Change
NET CHANGE
Cash From Operating Activities -$2.071M
Cash From Investing Activities -$28.00K
Cash From Financing Activities $47.01M
Net Change In Cash $44.91M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$2.071M
Capital Expenditures $28.00K
Free Cash Flow -$2.099M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458254 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5124182 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7820456 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1192600 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7115548 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3129552 USD
CY2014Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
265380 USD
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
274566 USD
CY2013Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
169568 USD
CY2014Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
286788 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14203995 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
136812406 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
0 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
218236 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2073694 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
97213 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
140132 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
201606 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
218236 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
654528 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
327264 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57850 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2013Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28925 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6508046 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6473893 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4404189 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6435036 shares
CY2013Q3 us-gaap Assets
Assets
18102620 USD
CY2014Q1 us-gaap Assets
Assets
63955147 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
63532689 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
17482407 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these condensed financial statements be read in conjunction with the financial statements and related notes that appear in Eagle Pharmaceuticals, Inc.'s (the "Company") final prospectus filed by the Company with the SEC on </font><font style="font-family:inherit;font-size:10pt;">February&#160;13, 2014</font><font style="font-family:inherit;font-size:10pt;">, relating to the Company's Registration Statement on Form S-1 (File No. 001-36306) for the Company's initial public offering. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made.&#160;Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ending September 30,</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2014</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter.</font></div></div>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.95
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10455565 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54879521 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3653426 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5066886 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
44423956 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1413460 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1372885 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3048131 shares
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1265654 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2557229 USD
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14020133 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3048131 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14020133 shares
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
3048 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
14020 USD
CY2014Q1 us-gaap Cost Of Revenue
CostOfRevenue
3359532 USD
us-gaap Cost Of Revenue
CostOfRevenue
1524291 USD
us-gaap Cost Of Revenue
CostOfRevenue
7983725 USD
CY2013Q1 us-gaap Cost Of Revenue
CostOfRevenue
1313135 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
10062296 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2014Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2013Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
171607 USD
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9694653 USD
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10019653 USD
us-gaap Depreciation
Depreciation
78500 USD
us-gaap Depreciation
Depreciation
59444 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
1666063 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.84
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-89239 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2696274 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-108332 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3723990 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
382630 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
573582 USD
CY2013Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3979236 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4803893 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8185081 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7234378 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-898703 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1294905 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1294905 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-325000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1742500 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
159419 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1320 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
144941 USD
us-gaap Interest Expense
InterestExpense
293103 USD
us-gaap Interest Expense
InterestExpense
1432 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
1432 USD
CY2013Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
164000 USD
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
328000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
1432 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1120 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
8821 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
482 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7557 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
180758 USD
CY2013Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
88301 USD
CY2014Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
72249 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
140353 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18102620 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63955147 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19268455 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14341805 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46507145 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-82482 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34616 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1500000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2048573 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2830978 USD
us-gaap Net Income Loss
NetIncomeLoss
-7286378 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-4803893 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2684331 USD
us-gaap Net Income Loss
NetIncomeLoss
-5939473 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8916308 USD
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3218172 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7605536 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5614689 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1001491 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-497778 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-376220 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-565908 USD
us-gaap Operating Expenses
OperatingExpenses
11147490 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
8607782 USD
us-gaap Operating Expenses
OperatingExpenses
17164801 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
6786949 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7183590 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3603016 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6668470 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4306115 USD
egrx Orphan Drug Exclusivity Regulatory Agency Stayof Application Maximum Period
OrphanDrugExclusivityRegulatoryAgencyStayofApplicationMaximumPeriod
P7Y
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
317817 USD
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
484833 USD
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69182 USD
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
212050 USD
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
31856 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46320 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
285 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2870 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
285 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2870 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2014Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
265000 USD
CY2013Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
265000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2463 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5157544 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34616 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
832712 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1902660 USD
CY2013Q3 us-gaap Prepaid Insurance
PrepaidInsurance
117510 USD
CY2014Q1 us-gaap Prepaid Insurance
PrepaidInsurance
620662 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
6500000 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46074674 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46487456 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
1500000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20868 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20868 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20868 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
402286 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
377458 USD
CY2014Q1 us-gaap Purchase Obligation
PurchaseObligation
1349199 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4743616 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3793789 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6382754 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2525001 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92139734 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102136057 USD
CY2013Q1 us-gaap Royalty Revenue
RoyaltyRevenue
1535824 USD
us-gaap Royalty Revenue
RoyaltyRevenue
6832881 USD
us-gaap Royalty Revenue
RoyaltyRevenue
2763570 USD
CY2014Q1 us-gaap Royalty Revenue
RoyaltyRevenue
3564776 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1200330 USD
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1174990 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3398450 USD
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
945010 USD
us-gaap Sales Revenue Net
SalesRevenueNet
3963900 USD
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
5004766 USD
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
2480834 USD
us-gaap Sales Revenue Net
SalesRevenueNet
10496331 USD
egrx Deferred Ipo Costs
DeferredIPOCosts
0 USD
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2948813 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4879583 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1454461 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2798322 USD
us-gaap Share Based Compensation
ShareBasedCompensation
218236 USD
us-gaap Share Based Compensation
ShareBasedCompensation
201607 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.64
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.3938
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.3434
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0825
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0253
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0323
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0323
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0082
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0095
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0082
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0175
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3450000 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46053806 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
-87929014 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
44686692 USD
CY2014Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
533841 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1629930 USD
CY2013Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
810796 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1666063 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
951405 USD
egrx Deferred Ipo Costs
DeferredIPOCosts
414026 USD
egrx Lawsuit Invoked Regulatory Stayof Approval
LawsuitInvokedRegulatoryStayofApproval
P30M
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed financial statements, actual results may materially vary from these estimates.</font></div></div>
CY2014Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 USD
CY2013Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1706829 USD
CY2013Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1309054 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5890949 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3048131 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8862212 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3023850 shares
CY2013Q3 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
62737 USD
CY2014Q1 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
15060 USD
CY2013Q3 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
282682 USD
CY2014Q1 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
757711 USD
egrx Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense
AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense
293103 USD
egrx Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense
AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense
0 USD
CY2012Q1 egrx Asset Purchase Agreement Royalty On Net Profitsof P Roducts Term
AssetPurchaseAgreementRoyaltyOnNetProfitsofPRoductsTerm
P10Y
egrx Classof Warrantor Right Expected Term
ClassofWarrantorRightExpectedTerm
P6Y
CY2008Q2 egrx Collaborative Product Development Agreement Cumulative Milestones Upon Achievementof Goals
CollaborativeProductDevelopmentAgreementCumulativeMilestonesUponAchievementofGoals
13000000 USD
CY2008Q2 egrx Collaborative Product Development Agreement Monthly Receivable
CollaborativeProductDevelopmentAgreementMonthlyReceivable
200000 USD
CY2008Q2 egrx Collaborative Product Development Agreement Non Refundable Amount Receivedfor Signing
CollaborativeProductDevelopmentAgreementNonRefundableAmountReceivedforSigning
750000 USD
CY2008Q2 egrx Collaborative Product Development Agreement Paymentfor Product Development
CollaborativeProductDevelopmentAgreementPaymentforProductDevelopment
2000000 USD
egrx Marketing Rights Term
MarketingRightsTerm
P10Y
CY2014Q1 egrx Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment
DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment
6000000 USD
CY2013Q3 egrx Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment
DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment
6000000 USD
CY2012Q1 egrx Expected Cash Proceeds Upon Regulatory Approval Milestone
ExpectedCashProceedsUponRegulatoryApprovalMilestone
1000000 USD
CY2014Q1 egrx Expected Cash Proceedson Additional Milestones Dependenton Licensor Sales Activity
ExpectedCashProceedsonAdditionalMilestonesDependentonLicensorSalesActivity
3000000 USD
egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
2085 USD
egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
9295 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-1069948 USD
CY2012Q1 egrx Milestonereductionfor Regulatory Approvalof Generic Competitor Minimum
MilestonereductionforRegulatoryApprovalofGenericCompetitorMinimum
500000 USD
egrx Orphan Drug Exclusivity Regulatory Agency Stayof Application Incremental Domestic Periodfor Pediatric Exclusivity
OrphanDrugExclusivityRegulatoryAgencyStayofApplicationIncrementalDomesticPeriodforPediatricExclusivity
P6M
CY2014Q1 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
0 USD
CY2013Q3 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1023291 USD
CY2013Q3 egrx Prepaid Product Costs
PrepaidProductCosts
730003 USD
CY2014Q1 egrx Prepaid Product Costs
PrepaidProductCosts
0 USD
egrx Product Development Agreements Exclusive Rights Acquired Numberof Products
ProductDevelopmentAgreementsExclusiveRightsAcquiredNumberofProducts
33 product
egrx Royalty Revenue Commercial Partners Obligationof Sales Report Term
RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm
P60D
CY2014Q1 egrx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1788 shares
egrx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1788 shares
egrx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
20868 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14020133 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Eagle Pharmaceuticals, Inc.

Files In Submission

Name View Source Status
0000827871-14-000010-index-headers.html Edgar Link pending
0000827871-14-000010-index.html Edgar Link pending
0000827871-14-000010.txt Edgar Link pending
0000827871-14-000010-xbrl.zip Edgar Link pending
egrx-20140331.xml Edgar Link completed
egrx-20140331.xsd Edgar Link pending
egrx-20140331_cal.xml Edgar Link unprocessable
egrx-20140331_def.xml Edgar Link unprocessable
egrx-20140331_lab.xml Edgar Link unprocessable
egrx-20140331_pre.xml Edgar Link unprocessable
egrx_q2x2014.htm Edgar Link pending
exhibit311.htm Edgar Link pending
exhibit312.htm Edgar Link pending
exhibit321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending